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ABSTRACT Amodiaquine plus artesunate is the recommended antimalarial treat-
ment in many countries where malaria is endemic. However, pediatric doses are
largely based on a linear extrapolation from adult doses. We pooled data from previ-
ously published studies on the pharmacokinetics of amodiaquine, to optimize the
dose across all age groups. Adults and children with uncomplicated malaria received
daily weight-based doses of amodiaquine or artesunate-amodiaquine over 3 days.
Plasma concentration-time proﬁles for both the parent drug and the metabolite
were characterized using nonlinear mixed-effects modeling. Amodiaquine pharmaco-
kinetics were adequately described by a two-compartment disposition model, with
ﬁrst-order elimination leading to the formation of desethylamodiaquine, which was
best described by a three-compartment disposition model. Body size and age were
the main covariates affecting amodiaquine clearance. After adjusting for the effect of
weight, clearance rates for amodiaquine and desethylamodiaquine reached 50% of
adult maturation at 2.8 months (95% conﬁdence interval [CI], 1.5 to 3.7 months) and
3.9 months (95% CI, 2.6 to 5.3 months) after birth, assuming that the baby was born
at term. Bioavailability was 22.4% (95% CI, 15.6 to 31.9%) lower at the start of treat-
ment than during convalescence, which suggests a malaria disease effect. Neither
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the drug formulation nor the hemoglobin concentration had an effect on any phar-
macokinetic parameters. Results from simulations showed that current manufacturer
dosing recommendations resulted in low desethylamodiaquine exposure in patients
weighing 8 kg, 15 to 17 kg, 33 to 35 kg, and 62 kg compared to that in a typical
50-kg patient. We propose possible optimized dosing regimens to achieve similar
drug exposures among all age groups, which require further validation.
KEYWORDS NONMEM, dose optimization, malaria, pediatrics
Approximately 3.2 billion people were at risk of Plasmodium falciparum malaria in2015, with an estimated 212 million malaria cases and 429,000 malaria-related
deaths occurring that year. Children under 5 years of age carry the highest burden of
disease, accounting for 70% of malaria-related deaths in 2015 (1). Artemisinin resistance
has been conﬁrmed in at least six countries in Southeast Asia (2–4). Thus, both the
choice of and correct dosing of artemisinin-based combination therapies (ACTs) are
crucial and should be driven by a comprehensive understanding of the pharmacoki-
netic (PK) and pharmacodynamic (PD) properties of both drugs in the combination.
Artesunate plus amodiaquine is one of the ﬁve ACTs currently recommended by the
World Health Organization (WHO) and has been adopted as a ﬁrst-line or second-line
treatment in at least 25 countries (5). Four different amodiaquine-based treatments are
available, including amodiaquine alone, coblistered amodiaquine plus artesunate (loose
combination), an amodiaquine-plus-artesunate ﬁxed-dose combination, and coblistered
amodiaquine plus sulfadoxine-pyrimethamine. A recent meta-analysis showed that amo-
diaquine plus artesunate administered in a ﬁxed-dose formulation results in efﬁcacy higher
than that of the other formulations (6).
Amodiaquine is primarily metabolized in the liver by cytochrome P450 (CYP) 2C8
(CYP2C8) to its biologically active metabolite, desethylamodiaquine (7–9), which is
thought to be the driver of the antimalarial activity (8, 10). Desethylamodiaquine is
eliminated slowly and has been detected in plasma and blood for up to 1 month after
drug administration (10). Desethylamodiaquine is further metabolized in vivo, via an
unknown route, into its inactive metabolite, bis-desethylamodiaquine (11). Both amo-
diaquine and desethylamodiaquine are over 90% protein bound (12) to 1-acid glyco-
protein (13).
Several studies have investigated dosing regimens for current antimalarial combi-
nation therapies (14–19). There is some concern that dosing recommendations may not
be optimal for some subgroups of patients, such as young and/or malnourished
children and pregnant women, due to altered PK properties in these vulnerable groups.
Several studies have investigated the PK of amodiaquine and desethylamodiaquine
using both model-based and model-independent analyses (20–25). However, to the
best of our knowledge, no studies have investigated the population PK of amodiaquine
and desethylamodiaquine across a broad range of ages by combining individual
patient-level data from different studies. Pooling of data from different populations
allows for the assessment of clinically important determinants affecting PK parameters
that might not be possible to investigate in smaller individual studies, and the large
amount of data provides more accurate and reliable parameter estimates.
The objective of this analysis was to investigate the PK of amodiaquine and
desethylamodiaquine by pooling data from previously published studies, using non-
linear mixed-effects modeling. The developed model was used to assess the current
dosing recommendations and to propose an improved dosing regimen, if necessary.
(This analysis was part of Ali Mohamed Ali’s Ph.D. work, so the information in this
article will be included in his Ph.D. dissertation.).
RESULTS
Thirteen relevant clinical studies were identiﬁed, of which eight were shared with
the WorldWide Antimalarial Resistance Network (WWARN). Two studies were contrib-
uted after the database for analysis was locked and were therefore not included. Data
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from 261 patients were available for PK analysis. Of these patients, 95 (36.4%) were
children under 5 years of age and 26 were pregnant women (21, 24). The median age
at the baseline across the studies was 7.6 years (interquartile range [IQR], 3.6 to 18
years; range, 1 to 60 years). All patients were infected with Plasmodium falciparum,
except for those in one study cohort from Asia (21, 24), which had Plasmodium vivax
monoinfections. The geometric mean baseline parasitemia was 24,400 parasites/l of
blood (IQR, 7,880 to 76.500 parasites/l of blood; range, 240 to 566,000 parasites/l of
blood) and 114 parasites/l of blood (IQR, 288 to 3,920 parasites/l of blood; range, 96
to 50,500 parasites/l of blood) in patients infected with Plasmodium falciparum and
Plasmodium vivax, respectively. Baseline values for each study population are presented
in Table 1, and detailed information can be found in the individually published reports
(20–25). Children from Burkina Faso (who were among the youngest) received a higher
total dosage (median, 33.8 mg/kg of body weight; range, 14.8 to 65.6 mg/kg) than the
other study populations (Kruskal-Wallis test, P  0.001) (Table 1).
A total of 2,920 postdose venous plasma samples for both amodiaquine and
desethylamodiaquine were collected, but the majority of patients (162/261; 62.1%)
contributed only 1 to 3 samples. Three studies (147 patients) collected samples for drug
measurements before the ﬁrst study dose, but only 1 (0.7%) amodiaquine concentra-
tion and 29 (19.7%) desethylamodiaquine concentrations were measured to be above
the lower limit of quantiﬁcation (LLOQ) (Table 2). Four (0.3%) samples for amodiaquine
and 37 (2.5%) samples for desethylamodiaquine were excluded from the analysis
because of unreliable information on the time of sample collection and/or because the
ﬁndings for those samples were deemed biologically implausible after inspection of the
PK proﬁle. In the ﬁnal analysis, 1,456 (99.7%) samples for amodiaquine and 1,423
(97.5%) samples for desethylamodiaquine were included. Out of these, the concentra-
tions in 803 (55.2%) samples for amodiaquine and 13 (0.9%) samples for desethylamo-
diaquine were below the LLOQ.
Population pharmacokinetic model. The observed amodiaquine data were best
described by a two-compartment disposition model, and two transit compartments
successfully described the absorption phase, while desethylamodiaquine was best
described by three-compartment disposition kinetics. Replacement of the structural
model with a semimechanistic hepatic model did not result in a better ﬁt and was not
pursued further. The use of the M3 method to handle LLOQ values did not signiﬁcantly
affect the population parameter estimates, but the model estimation process was
unstable and required much longer run times than the M6 method, which was
therefore used throughout the modeling process. The ﬁnal structural model is depicted
in Fig. 1, and the parameter estimates, together with their precision obtained from a
nonparametric bootstrap, are reported in Table 3.
The model adequately described all observed data from the included studies, as
shown by the study-stratiﬁed visual predictive check (VPC) plots in Fig. 2. VPCs stratiﬁed
by age and basic goodness-of-ﬁt diagnostic plots are presented in Fig. S1 and S2 in the
supplemental material, respectively. Even though some small trends can be observed
for amodiaquine for the ﬁrst hours after the dose in some of the contributed studies,
these plots showed no overall obvious model misspeciﬁcation and suggested that the
developed model has adequate predictive performance, especially for desethylamodi-
aquine, which is the main driver of the therapeutic outcome.
Covariate effect. Allometric scaling with body weight on all clearance and volume
parameters improved the model ﬁt substantially (change in the objective function
value [ΔOFV]  446). Inclusion of a maturation function for the clearance of deseth-
ylamodiaquine improved the model further (ΔOFV  34.6; 2 degrees of freedom [df];
P  0.001) and decreased the between-subject variability (BSV) of desethylamodi-
aquine clearance from 24% to 19.1%. A similar maturation effect did not reach statistical
signiﬁcance for amodiaquine (ΔOFV  3.1; 2 df; P  0.21) and decreased the BSV on
clearance only slightly, from 62.6% to 61.7%, but it was retained in the ﬁnal model for
consistency between the parent compound and the metabolite. The ﬁnal parameter
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estimates of the maturation function were close to the prior values used to stabilize the
model; clearance was found to reach 50% of weight-adjusted adult values at 2.8
months of age (95% conﬁdence interval [CI], 1.5 to 3.7 months of age) and 3.9 months
of age (95% CI, 2.6 to 5.3 months of age) (assuming a standard 9-month gestation) for
amodiaquine and desethylamodiaquine, respectively. The maturation effect is dis-
played in Fig. 3, which shows that 95% of the adult value is reached by 2 years of age.
Finally, the model estimated the bioavailability of the ﬁrst dose in the treatment
regimen to be 22.4% (95% CI, 15.6 to 31.9%) lower than that on the second and third
days of treatment (ΔOFV  18.9; 1 degree of freedom; P  0.001; decrease in the
between-occasion variability [BOV] on bioavailability, 33% to 31%). Inclusion of the
drug formulation and hemoglobin (HB) concentration on bioavailability did not im-
prove the model ﬁt, nor did the inclusion of the hemoglobin concentration on
amodiaquine or desethylamodiaquine clearance.
Variability. Even after adjusting for all covariate effects described above, a large
amount of BSV and BOV was still identiﬁed. A large BOV in absorption parameters
(78%), a large BSV in the central volume of distribution for both amodiaquine and
desethylamodiaquine (50%), a moderate BSV in clearance for both amodiaquine and
desethylamodiaquine (20 to 33%), and a moderate BOV for bioavailability (30.9%) were
observed. Moderate to high eta shrinkages (30 to 60%) were observed for parameter
estimates, while epsilon shrinkages were low (30%), as summarized in Table 3.
Simulations. The ﬁnal model was used to evaluate the exposure achieved with the
current dosing recommendations (26), and the results are summarized in Fig. 4A.
Children who weigh 8 kg, 15 to 17 kg, or 33 to 35 kg and patients who weigh 62 kg
achieve desethylamodiaquine day 7 concentrations that are, on average, 25% lower
than the concentration for a 50-kg patient. Population-based simulations using the ﬁnal
PK model suggested that higher dosages are needed to achieve equivalent exposures
in all body weight groups, raising the dosing recommendations for amodiaquine from
7.5 to 16.9 mg/kg/day to 9.8 to 19.9 mg/kg/day in certain patient groups (Fig. 4; Table
4). It is important to note that Fig. 4 shows simulated patients, including some with
ages below the age range of the observed data.
The predicted lower target concentration for efﬁcacy, i.e., 80% of the median
desethylamodiaquine concentration at day 7 in a 50-kg patient taking 540 mg daily for
3 days (15 mg/kg/day), was 54.0 ng/ml. The proposed optimized dosing regimen (Table
4) resulted in equivalent exposures across weight bands (Fig. 4B). In particular, higher
milligram-per-kilogram doses were needed for small children, consistent with the
nonlinear effect of body size on clearance, described by allometric scaling.
FIG 1 Structure of the PK model of amodiaquine and desethylamodiaquine. Abbreviations: F, oral bioavailability; KTR, ﬁrst-order
transit rate constant; Ka, absorption rate constant; AQ, amodiaquine; DEAQ, desethylamodiaquine; CL, clearance; Vc, central
volume of distribution; Q, Q1, and Q2, intercompartmental clearances; Vp, Vp1, and Vp2, peripheral volumes of distribution.
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FIG 2 Visual predictive check of the ﬁnal model describing the plasma concentrations of amodiaquine (AQ) and
desethylamodiaquine (DEAQ) versus time in uncomplicated malaria patients from Thailand (THA), Kenya (KEN), Uganda
(UGA), Burkina Faso (BKF), and Ghana (GHA). Open circles are the observed data points; solid and dashed lines are the
50th, 5th, and 95th percentiles of the observed data; shaded areas are the simulated (n 1,000) 95% conﬁdence interval
for the same percentile. The y axis represents the plasma concentration on the log scale. Censored data points below
the lower limit of quantiﬁcation were imputed as LLOQ/2 and included in the calculation of percentiles for the observed
and the simulation data. The VPC for amodiaquine for both Thailand and Kenya was cut at times of 90 and 60 h,
respectively, since beyond these times the concentrations from both observed and simulated data were below the LLOQ.
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DISCUSSION
This is the ﬁrst pooled population PK analysis of amodiaquine and desethylamodi-
aquine. The analysis used individual patient data from six studies (ﬁve cohorts) of the
antimalarial therapy amodiaquine, given alone or in combination with artesunate
(20–25), covering patient populations with a large range of characteristics (in terms of
weight, age, and ethnicity) and covering a large range of treatments and study
protocols. Consistent with other studies, the ﬁnal PK model included a two-
compartment model for the amodiaquine concentration-time proﬁle and a three-
compartment model for desethylamodiaquine. In addition to including the effect of
body size on the clearance of both compounds with allometric scaling, the maturation
proﬁle of the clearance of both compounds was included in the model to describe the
kinetics in children. To ensure exposure equivalent to that in adults, and hence
assuming that this would lead to improved efﬁcacy and curative concentrations,
simulations with the ﬁnal model of desethylamodiaquine indicated that higher doses of
amodiaquine may be needed for some weight ranges (8 kg, 15 to 17 kg, 33 to 35 kg,
and 62 kg), but this ﬁnding needs further validation.
The effect of the drug formulation or coadministration with artesunate on bioavail-
ability was not signiﬁcant in this analysis. Previously, efﬁcacy was found to be higher for
amodiaquine when given as a ﬁxed-dose formulation with artesunate (6), suggesting
that a ﬁxed-dose formulation may directly increase bioavailability or improve adher-
ence, leading to higher exposure, as measured by the area under the plasma
concentration-time curve (AUC). Only a few patients included in the analysis received
FIG 3 Clearance maturation for amodiaquine (red line) and desethylamodiaquine (blue line) expressed as a fraction of adult
clearance predicted from the PK model plotted against postnatal age (assuming that birth occurred at term). The dashed lines
indicate the section of the maturation curve that falls in the age range below that observed in the study data and are therefore
based on an extrapolation.
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FIG 4 Simulation results of current recommended and optimized dose regimens for amodiaquine. (A and C) Day 7 plasma
desethylamodiaquine concentration (A) and maximum concentration of desethylamodiaquine (C) based on the current
recommended dose regimen. (B and D) Predicted desethylamodiaquine day 7 concentration for the optimized dose
regimen designed to achieve a concentration 75% above the threshold value (B) and Cmax of desethylamodiaquine for
the optimized dose regimen (D). The black dashed and solid lines in panels A and B are the median and 80% value of
median of the simulated day 7 plasma desethylamodiaquine concentration for the typical patient (representing the
expected exposure level from the current dosing recommendation), respectively, and the red lines in panels C and D
represents the Cmax upper threshold (575 ng/ml). Simulations for each weight are presented as a box plot for the median
and 25th and 75th percentiles, with whiskers representing the 5th and 95th percentiles. The boxes in gray indicate that
the simulation for that age range is based on an extrapolation, since no PK data for children of that age were available.
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amodiaquine alone; this group included all of the patients from the Thailand study and
only 6% (15/256) of the patients from studies conducted in Africa. Moreover, the
patients treated with amodiaquine alone received a higher dose on a milligram-per-
kilogram basis than those that received the loose formulations or the ﬁxed-dose
combination therapy. These two factors possibly limited the power of the analysis to
explore formulation effects. Similarly, all pregnant patients and those infected with
Plasmodium vivax were from one study in Asia; thus, there was little power to separate
study-speciﬁc effects from any pregnancy, regional, or Plasmodium species effect on
the PK parameters.
The structural PK model identiﬁed here matches that proposed by Tarning et al. (21)
in pregnant women in Thailand. This is not surprising, since their study contributed the
most intensively sampled PK proﬁles included in this pooled analysis. Parameter
estimates were similar between the two analyses, but the central volume of distribution
was larger in this pooled analysis, and, as expected, pooling of data from several studies
resulted in a larger BSV (21). This could be due to differences in the body size and
composition between the Asian and African populations, or it could simply be a
consequence of different study sample sizes. Unfortunately, patient height data were
unavailable from the African studies, and other body size descriptors (i.e., fat-free mass
or body mass index) could not be explored as an alternative to total body weight.
Amodiaquine bioavailability was found to be 22.4% lower on the ﬁrst day of
treatment than on the second and third days, possibly due to an increased absorption
of amodiaquine as a result of treatment and a general improvement in malaria disease
status. Winstanley et al. (27) reported lower AUCs for amodiaquine in malaria patients
than in healthy volunteers, and this may be partly explained by the lower bioavailability
due to a disease effect that is more pronounced on the ﬁrst day than during conva-
lescence. Similarly, a nearly 2-fold (1.72-fold) relative increase in bioavailability has been
observed in studies of meﬂoquine, where administration is delayed until 48 hours after
the ﬁrst dose of artesunate (28). A similar increase in oral bioavailability during
treatment has been demonstrated in malaria patients receiving dihydroartemisinin-
piperaquine and for naphthoquine when given in combination with artemisinin in
pediatric malaria patients (29–32). In contrast, a higher bioavailability was estimated for
artesunate during the acute malaria phase than during the convalescent phase in a
recent study (33). Taken together, there might be an emerging trend of lower bioavail-
ability during acute phases of malaria illness for the longer-acting compound in ACT
treatments, warranting further investigation. A similar parallel has been noted with
antibiotic use in patients with sepsis (34).
The disease state may also alter absorption parameters (35), but the current analysis
could not assess the effect of acute illnesses on absorption, as it included only malaria
patients and not healthy individuals. There was considerable heterogeneity in malaria
symptoms and parasitemia, but attempts to include an effect of various parasite
densities in the model were unsuccessful, possibly because it was confounded by other
factors. The principal plasma protein binding site for amodiaquine is in 1-acid glyco-
TABLE 4 Current dose regimen and optimized dose regimen based on simulations for amodiaquine
Current manufacturer dose regimen Proposed dose regimen
Body wt (kg)
No. of tablets/day,
tablet strength
Total amodiaquine
dose (mg) Body wt (kg)
No. of tablets/day, tablet
strength (mg)
Total amodiaquine
dose (mg)
4 to 8 1, 67.5 67.5 4 to 6a 1, 67.5 67.5
9 to 17 1, 135 135 7 to 10b 1, 135 135
18 to 35 1, 270 270 11 to 16 1.5, 135c 202.5
36 2, 270 540 17 to 28 2.5, 135c 337.5
29 to 49 2, 270 540
50 3, 270 810
aA substantial number of simulated patients (78%) in this weight band were younger (1 year) than those available in the data set.
bA proportion of the simulated patients (38%) in this weight band were younger (1 year) than those available in the data set.
cIn these weight bands, as an alternative to splitting tablets, one could suggest using tablets of different strengths. Either option is viable, according to the preference
of the caregiver.
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protein (13), which is upregulated during malaria (36, 37), resulting in increased binding
of the drug to this protein. The variation in 1-acid glycoprotein levels could also
explain part of the high between-subject variability in the apparent volume of distri-
bution found in our analysis.
The large estimates of between-occasion variability could be a result of sparse data,
and some of the studies (23, 25) included in this analysis did not measure drug
concentrations on the ﬁrst and second days of treatment and/or provided only ap-
proximate information about the timing of sample collection (i.e., only the day and not
the exact time was available). Despite this, the effect of lower oral bioavailability for the
ﬁrst dose was conﬁrmed even in a separate analysis executed only on data from studies
that included sufﬁcient information.
PK parameter estimates from adults, adjusted for the effects of body weight and size
by allometric scaling, often provide poor predictions of drug clearance in young
children (38), especially for those less than 1 year of age. This is because PK can change
rapidly with postmenstrual age (PMA) (39–41) in the ﬁrst years of life. Age maturation
of clearance rates has been reported for various pediatric drugs (16, 42–45). In addition,
the clearance of amodiaquine depends on the enzyme CYP2C8, which is closely related
to CYP2C9 (46), whose isozymes are known to exhibit maturation effects (38). Similar to
the approach used in previous studies of other drugs (42, 44), a sigmoidal maximum-
effect function was used to model the maturation of clearance as a function of PMA. No
previous estimates have been presented for amodiaquine or desethylamodiaquine, but
the estimates of the PMA at which 50% enzyme maturation is achieved (PMA50)
presented here result in half-maximum maturation of amodiaquine and desethylamo-
diaquine clearance at 2.8 and 3.9 months after birth, respectively, for babies born at
term. This is in line with the range reported for other drugs (0.7 to 12 months after birth,
respectively, for babies born at term), as summarized by Holford et al. (47). The
estimates of the Hill coefﬁcients were also consistent with those reported in previous
studies (2 to 4), indicating a relatively sharp maturation curve plateauing at about 2
years after birth. Amodiaquine and desethylamodiaquine clearance reached at least
95% of the adult values at approximately 21 months after birth, suggesting that body
size is the main pharmacokinetic determinant for children older than 2 years of age.
Unfortunately, the present analysis did not include data from children younger than 1
year of age, most likely because children 1 year of age are commonly administered
artemether-lumefantrine or quinine; thus, few studies have investigated the PK of
artesunate-amodiaquine in infants 1 year of age. Due to the lack of available data for
young children, the parameter values of the maturation function are inﬂuenced by
information published for other drugs with CYP-dependent clearance. Other signiﬁcant
effects not included in our model may be relevant for very young children, including
limited absorption capabilities.
Appropriate drug dosing in children is particularly challenging (48), and a number
of studies have reported suboptimal dosing of children receiving antimalarial treatment
(14–19). Simulations presented in this analysis suggest that optimal plasma concentra-
tions require doses of amodiaquine higher than those currently recommended for
children weighing 8 kg, 15 to 17 kg, or 33 to 35 kg (Fig. 4). The same is true for patients
weighing 62 kg. The proposed alternative dosing guidelines were developed on the
basis of the strengths of currently available amodiaquine tablets, which are manufac-
tured in strengths of 67.5 mg and multiples thereof. The amodiaquine dose adjustment
proposed would increase complexity due to additional weight bands and would need
to be implemented with suitable additional training and tools (Table 4). However,
before routine implementation, the suggested regimen should be evaluated in pro-
spective trials for efﬁcacy and safety. Since amodiaquine and artesunate are often
coformulated in a ﬁxed-dose combination, the proposed dose changes would also
increase the artesunate dose from 2.8 to 6.3 mg/kg/day to 3.6 to 7.4 mg/kg/day, which
remains within the 2- to 10-mg/kg/day range recommended by WHO (49).
Simulations were used to propose optimized doses for the wide range of body
weights recommended by the manufacturers for artesunate-amodiaquine administra-
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tion (26). The simulated patients included very young children 2.5 to 15.2 months old
with weights of 4.5 kg to 6.0 kg, which are less than those of any of the patients for
which drug concentration-time data were available. For those patients, the proposed
optimized dosages are based on the inclusion of allometric scaling and, even more
critically, the maturation effect in very young children. Including these young children
in the simulations could provide some understanding of the expected exposure in this
group. Thus, the estimated exposure values and the suggested dose optimization in
this subgroup of the patients should be treated as extrapolations and interpreted with
caution. There is an urgent need to further investigate individuals in this age range.
The proposed new dosing recommendation suggests a substantial dose increase for
particular patient groups compared to the currently recommended values; e.g., the dose for
patients weighing 17 kg and 29 kg would change from 135 mg to 337.5 mg and 270 mg
to 540 mg, respectively. As a consequence of the dose increase, these patients will
experience higher peak concentrations, but the predicted median values of 560 ng/ml and
552 ng/ml for patients with weights of 17 kg and 29 kg, respectively, are within the range
of peak concentrations found in other clinical trials of amodiaquine (49).
This analysis assumes that the concentration threshold for efﬁcacy in the reference
patient of 50 kg is equally applicable to younger individuals. However, the exposures
required for efﬁcacy in children may be higher than those required for efﬁcacy in adults.
This is because children tend to have lower levels of partial immunity in areas where
malaria is endemic (50) and, consequently, higher parasite counts, lower hemoglobin
levels, and a higher risk of treatment failure and progression to severe malaria. Yet, data
on the safety of amodiaquine and any possible age dependence are limited. However,
it will be necessary to collect safety data for this new dose before implementation.
Further studies of the proposed dosing schedule are thus needed to conﬁrm safety and
efﬁcacy, especially in very young children.
As with all PK studies, there are limitations to the present analysis. Data for infants
younger than 1 year of age were not available, thus resulting in uncertainty in the
estimated maturation of clearance. Similarly, children younger than 12 years of age
contributed a median of two samples per patient. The concentrations of amodiaquine
were mostly below the LLOQ, making it difﬁcult to characterize the pharmacokinetics
of the parent compound in this age group. On the other hand, desethylamodiaquine
concentrations were generally detectable, and thus, it was possible to obtain, even in
this age group, a reasonably accurate description of the pharmacokinetics of the
metabolite, which is the main source of pharmacological action. The description of
pharmacokinetics in children was compensated for by including existing information
on the maturation of the enzymes involved in metabolizing amodiaquine. This step
made the estimates coherent with the general maturation proﬁle (i.e., the enzymes are
mature before 2 to 3 years of age), and it resulted in narrow bootstrap conﬁdence
intervals for the maturation parameters. Still, the results need conﬁrmation. Precise
information on the time of dose and/or the sampling time was not always available in
some studies; hence, it was assumed that the times were consistent with the protocol
schedule. In addition, different assays with different limits of quantiﬁcation were used
across the studies included in this analysis.
In conclusion, pooled individual concentration-time data for amodiaquine and its
metabolite (desethylamodiaquine) were described using population PK modeling. Amodi-
aquine was described accurately by a two-compartment disposition model followed by a
three-compartment disposition model for desethylamodiaquine. This study is the ﬁrst to
model the maturation of amodiaquine and desethylamodiaquine clearance as a function of
postmenstrual age and, hence, provides the basis for further analysis of whether infants and
young children achieve exposures equivalent to those in adults. The differences in amo-
diaquine PK between adults and children can largely be accounted for by body weight and
the maturation effect. Amodiaquine exposures after standard daily oral doses were lower
in small children and in patients weighing more than 62 kg. The body weight-adjusted
dosing regimen proposed in this study is expected to achieve similar exposure levels in all
patients without an increased risk of acute toxicity.
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MATERIALS AND METHODS
Clinical studies and data. This pooled analysis used data from previous studies conducted in
different populations and across different geographical locations. Clinical and PK data from six studies
(ﬁve cohorts) conducted in ﬁve countries (Burkina Faso, Ghana, Kenya, Uganda, and Thailand) were
shared with the WorldWide Antimalarial Resistance Network (WWARN) and used for this analysis (Table
2). Relevant studies were identiﬁed by searching PubMed, Embase, Google Scholar, ClinicalTrials.gov, and
conference proceedings, using the key words “amodiaquine pharmacokinetics” or “amodiaquine con-
centrations” and “clinical study.” The ﬁrst and last authors of relevant studies were contacted and invited
to join this pooled analysis. Participating authors agreed to the WWARN terms of submission, which
ensures that all data uploaded are anonymized and have been obtained with informed consent and in
accordance with any laws and ethical approvals applicable in the country of origin (51). Information
provided by each study included symptoms, dosing, drug concentrations, parasitemia, and clinical and
laboratory data over time. Patients were administered either amodiaquine monotherapy or artesunate
plus amodiaquine as a loose formulation or ﬁxed-dose combination therapy. Treatment was given once
daily for 3 days at a target dose of 10 mg/kg of body weight (Table 2). Data from 261 patients were
pooled. Patients reﬂected a wide range of ages (1 to 60 years) and weights (6.5 to 93 kg). Only 26
pregnant women were included in the data pool. Detailed information on recruitment of study participants,
randomization, and follow-up can be found in the reports of the respective studies (20–25). Information on
sample collection, storage, and the assays used is summarized in Table 2. Individuals were excluded from the
analysis if information on drug dosage was unavailable, while protocol times were imputed for patients with
missing information on the exact dosing times. All administered doses were converted to the amount of
amodiaquine base (in milligrams) before modeling. The data sets for each study were merged and formatted
for subsequent analysis using Stata software (version 11; StataCorp, College Station, TX, USA) according to the
Clinical Pharmacology Data Management and Statistical Analysis Plan (52, 53).
Structural model. Pharmacokinetic compartmental models were ﬁtted to the observed concentration-time
data for amodiaquine and desethylamodiaquine using nonlinear mixed-effects modeling with NONMEM
software (version 7.3; Icon Development Solutions, Ellicott City, MD). Amodiaquine and desethylamodi-
aquine concentration measurements were ﬁtted using the ﬁrst-order conditional estimation method (54)
with the eta-epsilon interaction. The Perl-speaks NONMEM, Xpose (version 4.3.5), Pirana (55), and R
(version 3.1.2) (56) programs were used for automation and diagnostics during the model-building
process. Nested models were assessed by their objective function value (OFV), computed by NONMEM
to be proportional to2 times the log likelihood of the data. A decrease in the OFV of at least 3.84 points
was considered a statistically signiﬁcant difference with P equal to 0.05, when comparing two hierarchical
models with one parameter difference (2 distribution with 1 degree of freedom [df]).
The structural (base) model was established using the most densely sampled clinical trial from the
pooled data. Subsequently, data from different studies were added one by one in order of data richness,
and each time the model was ﬁt to the new data, reassessed, and modiﬁed if necessary (57).
One-, two-, or three-compartment disposition models with ﬁrst-order elimination were investigated
for amodiaquine. First-order absorption models with and without lag time and transit compartment
absorption (58) were tested to describe drug absorption. Thereafter, the parameters for the best-
performing amodiaquine model were ﬁxed to the ﬁnal estimates, and the structural disposition model
for desethylamodiaquine was investigated. Amodiaquine was assumed to be completely and irreversibly
metabolized to desethylamodiaquine (7), and a molar conversion factor was included to account for the
difference in molecular weight between the two compounds. One-, two-, and three-compartment
disposition models with ﬁrst-order elimination were evaluated for desethylamodiaquine. Finally, the
amodiaquine and desethylamodiaquine concentrations were ﬁtted simultaneously and the model was
reevaluated. Additionally, we tested a semiphysiological model with hepatic extraction, implemented as
previously described (59), with the aim of describing both hepatic clearance and ﬁrst-pass extraction
using the single parameter of hepatic intrinsic clearance (12, 60).
Several approaches to handling values below the lower limit of quantiﬁcation (LLOQ) were tested (61,
62), ignoring the data below the LLOQ (M1), imputing LLOQ/2 for the ﬁrst value in a consecutive series
followed by ignoring the subsequent data below LLOQ (M6), or applying a likelihood-based approach
(M3). Model stability and the robustness of the parameter estimates, as well as model run times, were
considered when deciding on the approach for handling data below the LLOQ. All data below the LLOQ
were retained in simulation-based diagnostics, i.e., visual predictive checks (VPCs).
Effect of body size and age. The impact of body weight was evaluated by allometric scaling of all
clearance (exponent of 0.75) and volume (exponent of 1) parameters for amodiaquine and desethyla-
modiaquine, considering the strong biological prior of this relationship (47). A maturation function was
investigated to characterize the age-related changes in clearance (39, 63). The individually predicted
value of clearance was obtained by combining both the effect of size (allometric scaling) and the
developmental process (maturation function), as shown in Equation 1:
CL CLTV ·  BWBWTV
3⁄4
·
PMAHill
PMAHill PMA50
Hill (1)
where PMA is postmenstrual age (gestational age plus postnatal age), PMA50 is the PMA at which 50%
enzyme maturation is achieved, and Hill is a shape factor for the relationship. CL is clearance, CLTV is the
clearance for a typical patient, BW is the individual body weight, and BWTV is the body weight of a typical
patient.
The reason for using PMA for the maturation function is that maturation begins in utero (39) and at
birth organs have already achieved a certain level of maturation. No information on the duration of
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gestation for the individual children was available, so PMA was obtained by simply adding 9 months to
the postnatal age, assuming no premature births. For ease of interpretation, the results are presented
and discussed in terms of postnatal age for a baby born at term. As no data were available for children
younger than 1 year of age (among the studies included), prior information was used to stabilize the
parameters of the maturation function to physiologically plausible values, comparable to those used for
other drugs (16, 40, 42–44, 64). The Prior functionality in NONMEM was employed for this (65), assuming
weakly informative priors (10% uncertainty) for the maturation curve and using values of 12 months for
PMA50 and 3.5 for the Hill coefﬁcient. These values are in line with the maturation proﬁle of CYP450
enzymes (46) and generally in line with the maturation of most drug elimination pathways (47), so they
were considered reasonable priors for amodiaquine, which is mainly metabolized by CYP2C8 (7–9).
Stochastic model. A log-normal distribution was assumed for between-subject variability (BSV) and
between-occasion variability (BOV) in the PK parameters. The unexplained residual variability was
modeled using a combined additive and proportional error model.
Drug concentration data from the different studies were obtained from different laboratories and
with assays characterized by different limits of quantiﬁcation, which might confer a different precision in
the quantiﬁcation of the lower concentrations in the pharmacokinetic proﬁle. To account for this
difference, we attempted to estimate a separate residual error for each study, but this proved unstable
and resulted in the data sets with sparser sampling schedules being assigned unrealistically small errors
and thus being overﬁt. As an alternative, we decided to conservatively add 20% of the LLOQ of each
speciﬁc study to the estimated additive error component for the samples obtained in that study (Table
2). The value of 20% was chosen to remain consistent with the error level threshold generally used by
analytical laboratories to deﬁne the limit of quantiﬁcation when assays are developed according to drug
development regulatory standards (66).
Whenever amodiaquine or desethylamodiaquine concentrations were detectable in the predose
samples, those observed values were used to initialize all disposition compartments in the model to
account for the prior presence of that drug in the body.
Covariate analysis. Predeﬁned covariates considered for inclusion, besides weight and age (dis-
cussed above), were sex, drug combination (amodiaquine administered alone or in combination with
artesunate) and formulation (loose formulation or ﬁxed-dose combination), and the plasmodium species.
A disease effect and any possible effects related to the patient’s improving condition with treatment
were investigated by testing the total parasite count and the hemoglobin (HB) concentration both at the
baseline and on the days after initiating treatment and exploring whether the PK parameters varied after
the initiation of treatment. Only three patients (1.2%) had missing parasitemia at the baseline; for these
patients, the median value for their respective study population was used instead. Since some studies
reported hematocrit (HT) and not hemoglobin (HB), the latter was estimated using equation 2 (67).
HB
HT 5.62
2.60
(2)
The effect of covariates on PK parameters was assessed by using linear or exponential models for
continuous covariates and additive proportional models for categorical covariates and by using a
stepwise forward inclusion (P  0.05) and backward elimination (P  0.001) approach (68).
Model assessment. Model development was guided by improvements in the OFV, using the
likelihood ratio test, and inspection of goodness-of-ﬁt and other diagnostic plots. VPCs (69) stratiﬁed by
country and age group were produced using Perl-speaks-NONMEM (PsN) with 1,000 simulations from the
original data set. Eta and epsilon shrinkages were used to assess the reliability of empirical Bayes
estimates and the power to detect model misspeciﬁcations in goodness-of-ﬁt diagnostics (70). A
nonparametric bootstrap with replacement (n  500) was used to evaluate the robustness of the
parameter estimates of the ﬁnal model.
Simulations. Monte Carlo simulations were performed using the ﬁnal PK model to explore the
expected exposure and to evaluate optimal dosing regimens across different body weights. To ensure
that the model would reﬂect exposure in accordance with the dosing guidelines for a speciﬁc population,
in particular, underweight malaria parasite-infected children, in silico patients were generated by using
individual demographic values (age and weight) from the studies included in the current analysis, plus
other historical data (n  748) from malaria patients (71–73) and routine clinical monitoring data for
1,580 children collected from the Bagamoyo Research and Training Center, a branch of the Ifakara Health
Institute in Tanzania (unpublished). Pooling all these data, we obtained a database with 2,600 in silico
patients covering a wide range of ages (2.5 months to 71.1 years) and body weights (4.5 to 93 kg). It is
important to note that the age range of the patients used for simulations included ages lower than those
for the children used to develop the ﬁnal PK model.
Simulations using the ﬁnal population PK model were repeated 5,000 times for each individual in
silico patient. Subsequently, 3,000 exposures in each 1-kg weight band (1-kg intervals) were randomly
drawn from the simulated results.
Desethylamodiaquine concentrations on day 7 were used as a proxy for efﬁcacy, since they have
been reported to correlate well with clinical cure rates (74). However, no target concentration value
associated with clinical success is available in the published literature. The current dosing recommen-
dation (49) results in reasonable cure rates in adults, suggesting that the exposure in a typical 50-kg adult
with malaria is sufﬁcient for treatment success. Thus, the simulated day 7 plasma concentration of
desethylamodiaquine in this typical patient was assumed to be the relevant target concentration
associated with clinical treatment success. The proposed dosing regimen was developed so that 75% of
the patients in each 1-kg weight band were predicted to have day 7 desethylamodiaquine concentra-
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tions that were at least 80% of the target concentration. Also, the predicted maximum concentration
(Cmax) of desethylamodiaquine was monitored to evaluate potential acute toxicity associated with
increased dosing. The predicted 75th percentile of Cmax in the patient weight group with the highest
concentrations after receiving the currently recommend dosing was selected as a target level for
potential acute toxicity. This reference target value was compared with the simulated exposures with the
proposed dosing guidelines. Safety was assumed if the peak concentrations seen with the proposed
guidelines did not signiﬁcantly exceed the values already experienced by some patients with the current
dosing recommendations.
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